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See related article on page 929. Resection of early-stage non-small cell lung cancer (NSCLC) re-mains the standard of care for patients whose condition is consid-ered operable on the basis of the following criteria: Complete (R0)resection is technically achievable; postresection pulmonary func-tion is adequate; and coexisting medical conditions do not contra-indicate general anesthesia and surgery. Although anatomic resec-
tion is considered the optimal procedure for NSCLC, some patients, who could not
tolerate lobectomy, may nevertheless benefit from more limited (wedge) resection.
In addition, selected patients with isolated pulmonary metastases may benefit from
limited pulmonary resection, based on the following criteria: The primary malignant
tumor is controlled; there is no evidence of extrathoracic disease; the pulmonary
involvement is considered completely resectable with adequate postresection pul-
monary reserve; and no other therapy (medical) is considered effective.
Despite advances in perioperative care and understanding regarding operability
for patients with advanced pulmonary dysfunction,1 some patients with potentially
curable disease are not candidates for surgical resection because of coexisting
medical conditions. External beam radiation is considered the most reasonable
alternative for patients with early-stage lung cancer who are not operative candi-
dates; however, regional complications such as radiation pneumonitis, fibrosis, and
esophagitis may limit efficacy. Furthermore, conventional radiation therapy is not
indicated for pulmonary metastases.
Noninvasive strategies, applicable to patients considered “medically inoperable,”
that are being developed to manage malignant pulmonary disease include stereo-
tactic radiotherapy, brachytherapy, photodynamic therapy, bronchial artery infusion
of chemotherapy, cryotherapy, and radiofrequency ablation (RFA). As these tech-
niques evolve, one would expect application to patients whose malignant tumors
should be considered operable and completely resectable. Thus, the development of
these techniques must be scrutinized to ascertain safety, efficacy, and applicability.
In this issue of the Journal, the efficacy of RFA for malignant pulmonary disease,
including early-stage lung cancer and isolated pulmonary metastases, is examined in
patients who could not tolerate pulmonary resection.2 This study is important
because it emphasizes the role of thoracic surgeons in evaluating nonoperative
strategies in this population; emerging technologies are already being investigated
and applied by others. RFA, which already has been accepted for the treatment of
hepatic malignant disease, is being advanced for treatment of pulmonary malig-
nancy by interventional radiologists. As well, other nonsurgical therapies are being
developed for patients with early-stage lung cancer, such as stereotactic radiosur-
gery by radiation oncologists3 and photodynamic therapy by pulmonologists.4
Thoracic surgeons should be involved with the evaluation of these new technologic
advances, and the authors should be commended for their effort.
RFA does appear to be safe, at least under the conditions of this study, in which
an operating room equipped with a computed tomographic scanner was used. It is
difficult to ascertain the efficacy of RFA in the current study, as there are no defined
exclusion criteria. It appears that patients were included in this study who would not
have been offered any type of therapy, even if medically operable, under the premise
that RFA carries such a minimal risk. As well, it is not clear that patients who
recently received other therapy were uniformly excluded. Clearly, at least one patient
received recent brachytherapy. Treatment response cannot be attributed to RFA if this
is the case. Nevertheless, this technology does appear to be effective in selected patients,
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and a formal phase 2 clinical trial, evaluating patients with
primary NSCLC less that 5 cm in diameter or with isolated
(3) pulmonary metastases should be designed.
Most important, the evaluation of technologies to
achieve nonsurgical local control of malignant pulmonary
disease must be designed and conducted by thoracic sur-
geons, in conjunction with medical oncologists, radiation
oncologists, interventional radiologists, and pulmonologists.
The investigations must analyze outcome, risk/benefit ratio,
and cost and should be designed to answer a scientific question
rather than demonstrate a proprietary strategy. The study by
Herrera and colleagues2 is an important primary step in the
evaluation of RFA for the treatment of patients with malignant
pulmonary disease who are not considered surgical candidates.
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